Volume 7.26 | Jul 9

Mammary Cell News 7.26 July 9, 2015
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MCN on Twitter
Treating Breast Cancer with Progesterone Could Aid Survival
Researchers discovered how receptors that mediate activity of the female sex hormones (estrogen and progesterone) interact with DNA to control the growth of a large majority of breast cancers. [Press release from University of Adelaide discussing online prepublication in Nature] Press Release | Abstract
Request your FREE copy of STEMCELL Technologies' new 2015 catalog!
PUBLICATIONS (Ranked by impact factor of the journal)

Promotion of BRCA2-Dependent Homologous Recombination by DSS1 via RPA Targeting and DNA Mimicry
Researchers found that replication protein A (RPA)-RAD51 exchange requires the BRCA2 partner DSS1. Biochemical, structural, and in vivo analyses reveal that DSS1 allows the BRCA2-DSS1 complex to physically and functionally interact with RPA. [Mol Cell] Abstract | Graphical Abstract | Press Release

Decreased LRIG1 in Fulvestrant-Treated Luminal Breast Cancer Cells Permits ErbB3 Upregulation and Increased Growth
LRIG1 overexpression improved fulvestrant-mediated growth inhibition, whereas cells expressing the LRIG1 mutant were poorly sensitive to fulvestrant, despite effective ERα downregulation. [Oncogene] Abstract

RING Finger Protein 31 Promotes p53 Degradation in Breast Cancer Cells
RNF31 depletion in breast cancer cells in combination with global gene expression profiling revealed p53 signaling as a potential RNF31 target. RNF31 decreased p53 stability, whereas depletion of RNF31 in breast cancer cells caused cell cycle arrest and cisplatin-induced apoptosis in a p53-dependent manner. [Oncogene] Full Article

IL-17A and Its Homologs IL-25/IL-17E Recruit the c-RAF/S6 Kinase Pathway and the Generation of Pro-Oncogenic LMW-E in Breast Cancer Cells
Investigation of the molecular signaling following stimulation of human breast cancer cell lines with IL-17A and IL-17E showed that both cytokines induced the phosphorylation of c-RAF, ERK1/2 and p70 S6 kinase were involved in the proliferation and survival of tumor cells. [Sci Rep] Full Article

The Chemomodulatory Effects of Resveratrol and Didox on Herceptin Cytotoxicity in Breast Cancer Cell Lines
The authors investigated the influence of resveratrol and didox on the cytotoxicity profile of herceptin in HER-2 receptor positive and HER-2 receptor negative breast cancer cell lines [Sci Rep] Full Article

Estrogen Receptor α Regulates Non-Canonical Autophagy that Provides Stress Resistance to Neuroblastoma and Breast Cancer Cells and Involves BAG3 Function
Researchers characterized tumor cell lines ectopically expressing estrogen receptor (ER)α or ERβ as well as the breast cancer-derived MCF-7 cell line endogenously expressing ERα but being ERβ negative. [Cell Death Dis] Full Article

Histone Deacetylase Inhibitor Entinostat in Combination with a Retinoid Downregulates HER2 and Reduces the Tumor Initiating Cell Population in Aromatase Inhibitor-Resistant Breast Cancer
Scientists investigated whether combining all-trans retinoic acid and histone deacetylase inhibitor entinostat can inhibit tumor initiating cells and HER2 in aromatase inhibitor-resistant cells and tumors. [Breast Cancer Res Treat] Abstract

Extracellular Vesicles from Women with Breast Cancer Promote an Epithelial-Mesenchymal Transition-Like Process in Mammary Epithelial Cells MCF10A
The authors studied whether extracellular vesicles from plasma of women with breast cancer are able to induce an epithelial-mesenchymal transition process in mammary epithelial cells MCF10A. [Tumor Biol] Abstract

Evaluation of MCF10A as a Reliable Model for Normal Human Mammary Epithelial Cells
When grown in suspension culture, MCF10A cells showed low mammosphere-forming ability. Cells in mammospheres and three-dimensional (3D) culture expressed both luminal and basal markers. The acinar structure formed by MCF10A cells in 3D culture was positive for both basal markers and the milk proteins β-casein and α-lactalbumin. [PLoS One] Full Article


Phase I/II Trial of Neoadjuvant Sunitinib Administered with Weekly Paclitaxel/Carboplatin in Patients with Locally Advanced Triple-Negative Breast Cancer
Investigators evaluated the feasibility and efficacy of adding sunitinib to paclitaxel/carboplatin in the neoadjuvant therapy of patients with triple-negative breast cancer. [Breast Cancer Res Treat] Abstract

Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers
Researchers analyzed the effects of methods of risk estimation and bias correction and of population factors on cumulative lifetime risks in this retrospective clinical cohort of BRCA1/2 carriers. [J Clin Oncol] Abstract

See Who's Published: Leading Breast Cancer Researchers Use MammoCult™
There and Back Again: The Journey of the Estrogen-Related Receptors in the Cancer Realm
The authors discuss how the estrogen-related receptors occupy a central node at the interface of cancer and metabolism, and that modulation of their activity may represent a worthwhile strategy to induce metabolic vulnerability in tumors of various origins and thus achieve a more comprehensive response to current therapies. [J Steroid Biochem Mol Biol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Prima Biomed Receives Positive Scientific Advice from the European Medicines Agency for Its Lead Product, IMP321
Prima BioMed Ltd announced that it has received positive scientific advice from the European Medicines Agency on the development path for its lead product IMP321 in metastatic breast cancer. [Prima BioMed Ltd] Press Release

Celsion Announces Continuing Positive Data from Its Phase II DIGNITY Study in Breast Cancer
Celsion Corporation announced positive interim data from its ongoing open-label Phase II DIGNITY Trial of ThermoDox® in recurrent chest wall breast cancer. [Celsion Corporation] Press Release

$1.8 Million NCI Award Helps Researcher Study Protein’s Effect on Breast Cancer
Xiaoting Zhang, PhD, associate professor in the Department of Cancer Biology at the University of Cincinnati College of Medicine, has received a $1.8 million, five-year, R01 award from the National Cancer Institute (NCI) to continue breast cancer research focusing on the function of the protein MED1 on HER2-positive breast cancer. [University of Cincinnati College of Medicine] Press Release

Matthew Ellis Receives Stand Up to Cancer’s Laura Ziskin Prize for Breast Cancer Research
Dr. Matthew Ellis, director of the Lester and Sue Smith Breast Center at Baylor College of Medicine, has received the Stand Up To Cancer 2015 Laura Ziskin Prize to advance studies of the defective DNA repair mechanisms in breast cancer. [Baylor College of Medicine] Press Release

Cancer Research UK Invests £15 Million in New Major Centers
Cancer Research UK launches major centers in Oxford, Manchester and Cambridge, with each receiving £5 million to boost their work in personalized cancer medicine and early detection research. [Cancer Research UK] Press Release

OHSU Sets Fundraising Record by Meeting $1 Billion Challenge from Nike Co-Founder and Wife
Oregon Health & Science University (OHSU) announced it met Nike co-founder Phil Knight and his wife Penny’s $1 billion challenge by raising $500 million in less than two years to earn the Knights’ matching gift and set a fundraising record. [Oregon Health & Science University] Press Release

From our sponsor: Learn about air-liquid interface culture for respiratory research. Watch the video.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 3rd International Annual Conference of the German Stem Cell Network (GSCN)
September 9-11, 2015
Frankfurt, Germany

Visit our events page to see a complete list of events in the mammary cell community.
NEW Research Associate/ Assistant Professor – Breast Cancer (University of Chicago)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Senior Product Manager – Breast Cancer (Celgene Corporation)

PhD Position – Anti-Cancer Nano-Particle Drug Testing (University of Southern Denmark)

Postdoctoral Research Associate – Breast Stem Cell Biology (University of Miami Miller School of Medicine)

Postdoctoral Researcher – Breast Cancer (University of Oxford)

Postdoctoral Fellow – Oncolytic Viruses (Mayo Clinic – Rochester)

Postdoctoral Positions – Breast Cancer (University of Texas MD Anderson Cancer Center)

Assistant/Associate/Full Professor – Oncology (Shanghai Jiao Tong University School of Medicine)

Postdoctoral Position – Fatty Acid Metabolism Inhibition on Chemoresistant TNBC Models (University of Girona)

Postdoctoral Fellow – Regulation of Growth and Survival of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us